ACYLATED CYCLODEXTRIN DERIVATIVES

Abstract: A cyclodextrin derivative, wherein at least 60 percent of the free hydroxy groups of said cyclodextrin are acylated with acyl groups where at least one of said acyl groups comprise a free carboxylic group.

Description: ACYLATED CYCLODEXTRIN DERIVATIVES Background of the Invention In 1904, Schardmger first characterized cyclodextnns as cyclic oligosaccharides . The a , β , and γ-cyclodextnns, which consist of six, seven, and eight glucose units, respectively, are the most common natural cyclodextnns . Cyclodextnns have been used as inclusion complexes by complexmg with a guest compound or molecule as a host compound or molecule. Such inclusion complexes have been used to mask the bitter taste or unpleasant odor of a guest compound, to solubilize a hardly soluble guest compound, to enlarge the stability of a guest compound against heat, light, or air, to stabilize emulsions, or as a sustained release preparation using a hydrophobic alkylated cyclodextrin. See U.S. Patent No. 4,869.904. However, no one has attempted to make carboxyacylated cyclodextnns, or used such cyclodextrin derivatives to form ionic sustained release compositions. Summary of the Invention In one aspect, the present invention features a cyclodextrin derivative, wherein at least 60 (e.g., between 75 and 100) percent of the free hydroxy groups of the cyclodextrin are acylated with acyl groups where at least one of the acyl groups comprises a free carboxylic group. What is meant by cyclodextrin is a cyclic oligosaccharide . Examples of cyclodextnns include a- cyclodextπn, 3-cyclodextrm, or γ-cyclodextπn. In one embodiment the acyl groups are selected from COE^ where E ± is selected from the group consisting of C 2 32 carboxy alkyl , C 3 33 carboxy alkenyl, C 737 carboxyaryl , C 838 carboxyaryl alkyl , and C 939 carboxyaryl alkenyl, and COE 2 , where E 2 is selected from the group consisting of C x 30 alkyl, C 230 alkenyl, C 636 aryl , C 737 arylalkyl, and C 8 _ 38 arylalkenyl, wherein at least one of the acyl group is . In a further embodiment, between 10 and 80 (e.g., between 30 and 80) percent of the free hydroxy groups of the cyclodextrin are acylated with COE j^ and between 10 and 80 (e.g., between 15 and 60) percent of the cyclodextrin are acylated with C0E 2 . In still a further embodiment, E x is C 2 _ 10 carboxy alkyl (e.g., CC^ is CO(CH 2 ) n COOH (where n = 2-3)) and E 2 is C x _ 10 alkyl (e.g., COE 2 is CO(CH 2 ) n CH 3 (where n = 0-5)). In another aspect, the invention features a copolymer comprising the cyclodextrin derivative described above, wherein the cyclodextrin derivative comprises at least one free hydroxy group which is acylated with a polyester comprising hydroxy acid monomers. In one embodiment, the copolymer has an average molecular weight of between 500 - 40,000 daltons (e.g., 500 - 10,000). In a further embodiment, the polyester comprises hydroxy acid monomers selected from the group consisting of lactic acid, glycolic acid, hydroxy caprolic acid, or any optically active isomer thereof. Such polyesters can be manufactured by reacting said cyclodextrin derivative with lactide, glycolide, caprolactone, p-dioxanone, trimethyl carbonate, or any optically active isomer thereof. In still another aspect, the invention features a composition comprising the cyclodextrin derivative described above and a drug, the drug comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of the polypeptide present in the composition is ionically bonded to the cyclodextrin derivative. In one embodiment, the composition comprises between 1 and 30 (e.g., between 10 and 20) percent, by weight, of the drug. In a further embodiment, the drug is a polypeptide. In still a further embodiment, the polypeptide comprises between 4 and 200 amino acids (e.g., between 4 and 50 ammo acids) . Examples of the polypeptide include somatostatm, bombesm, calcitonm, amylm, parathyroid hormone, parathyroid hormone related protein, gastπn releasing peptide, lutemizmg hormone releasing hormone, growth hormone, growth hormone releasing factor, terferons, erythropoietm, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, pituitary adenylate cyclase activating polypeptide, vasoactive intestinal peptide, thyrotropm releasing hormone, corticotrop releasing hormone, Acetyl-Ser-Asp-Lys-Pro, argmme vasopressm, angiotensm, and any fragments, agonists, or antagonists thereof. In yet another aspect, the invention features a composition comprising the copolymer described above and a drug, the drug comprising at least one effective lonogenic am e, wherein at least 50 percent, by weight, of the polypeptide present in the composition is lonically bonded to the cyclodextrin derivative. In one embodiment, the composition comprises between 1 and 30 (e.g., between 10 and 20) percent, by weight, of the drug. In a further embodiment, the drug is a polypeptide . As used herein, "lower alkyl" is intended to include both branched and straigh -chain saturated aliphatic hydrocarbon groups. Examples of lower alkyl groups include methyl, ethyl, propyl , isopropyl, butyl, t-butyl, isobutyl, sec-butyl, and the like. "Lower alkenyl" groups include those branched and straight chain aliphatic hydrocarbon groups having one or several double bonds. Examples of alkenyl groups include vinyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl , 1-propenyl, 2- butenyl , 2 -methyl -2 -butenyl , isoprenyl, and the like. All alkyl, alkenyl, and alkynyl groups are noncyclic. As used herein, "aryl" is intended to include any stable monocyclic, bicyclic, or tπcyclic carbon rmg(s) of up to 7 members m each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl , anthracenyl, biphenyl, tetrahydronaphthyl, mdanyl, phenanthreynl, and the like. The term "carboxy" is meant to include the recited chemical group (e.g., alkyl, alkenyl, aryl, arylalkyl, arylalkenyl) substituted with 1 to 3 carboxy groups. Other features and advantages of the present invention will be apparent from the detailed description of the invention, and from the claims. Description of the Invention It is believed that one skilled m the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure m any way whatsoever. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. Example 1 : Preparation of Acylated / S-Cyclodextrm (ACD) Cyclodextrin (Amaizo, American Maize Products Corp. Hammond, IN) was dried at 90 °C under reduced pressure (0.1 mm Hg) to a constant weight. Dried cyclodextrin (CD) was then transferred to a reaction flask equipped for stirring. After purging with argon, the CD was heated at 50°C for 30 mm. at 0.1 mm Hg, cooled to 25 °C, and repurged with dry argon. Calculated amount of the acylating reagent, as a liquid anhydride (except in ADC No. 1 where the anhydrides were dissolved in 15 ml of acetic acid) , containing a catalytic amount (i.e., 1 percent by weight) of p-toluene sulfonic acid (except in ACD No. 1 and ACD No. 2 where 1 percent H 2 S0 4 was used instead of p-toluene sulfonic acid) was transferred to the reaction flask, mixed under a dry argon atmosphere, and then heated. The amount of CD and acylating agents used as well as the heating scheme is described in Table I. At the conclusion of the reaction, the resulting mixture was allowed to cool slightly and then poured on to a vigorously stirring ice-water mixture. The resulting precipitate was filtered, rinsed several times with cold water, and air dried. The product was then isolated and dried until constant weight under vacuum, first at 25°C and then 50°C. The product was characterized for equivalent weight, as reported in Table I, by measuring titratable carboxylic acid functionally using benzyl alcohol solution of the product and potassium hydroxide in benzyl alcohol with bromophenol red as an indicator. TABLE I . Preparation and Properties of Acylated jβ-Cyclodextrms (ACD) ACD REACTANTS 1 HEATING SCHEME EQUIVALENT No. Temp (°C)/ WEIGHT Time (min. ) (Da) 1 51. Og CD, 55. Og A 28.7g S 95/180 1104 2 25.5g CD, 28. lg A 14.4g S 95/135 874 3 12.8g CD, 9.69g A 10.8g G 95/120 561 4 12.8g CD, 18. Og P 8.20g G 95/15, 100/30; 829 and 105/30 5 12.7g CD, 12.2g P 10.7g G 90/60 657 6 12.7g CD, 10. lg P 13.9g G 70/20 524 7 12.7g CD, 10. lg P 13.9g G 60/10 and 65/30 511 8 12.7g CD, 12.3g B 13.9g G 60/10 and 65/45 574 9 12.7g CD, 8.90g B 20.5g G 65/10 and 60/50 401 10 12.7g CD, 5.31g B 20.4g G 65/5 and 60/50 346 CD is β-Cyclodextrin, A is Acetic Anhydride, P is Propionic Anhydride, B is Butyric Anhydride, S is Succinic Anhydride, and G is Glutaπc Anhydride Example 2 : Grafting Acylated Cyclodextrin (G-ACD) with Lactones Predetermined amounts of the above acylated cyclodextrin derivative (ACD) , lactone or mixture of lactones, and a catalytic amount (i.e., <0.2 percent by weight) of stannous octoate were transferred to a dry polymerization flask equipped for stirring, under an inert dry atmosphere. The amount of ACD and lactones used are described m Table II. The mixture was then heated under vacuum at about 45°C for 30 min. , cooled to room temperature, and then purged with dry argon. The reactants were then heated while stirring as described Table II. At the conclusion of the reaction, the temperature was lowered to abut 110°C, and vacuum was applied for 0.5 to 1 hr . to remove distillable volatiles. The polymerization flask was cooled to room temperature and purged with argon. The grafted copolymer product (G- ACD) was isolated, dissolved in acetone, and then precipitated in ice water. The precipitate was filtered and air dried. The resulting powder was further dried under vacuum to a constant weight . The product was characterized for equivalent weight, as reported in Table II, by measuring titratable carboxylic acid functionality. TABLE II. Preparation of Lactone-Grafted ACD (G-ACD) G is glycolide, L is D,L-Lactide, and CL is e -Caprolactone Example 3 : Preparation of Polypeptide Composition Containing of Acylated β-Cyclodextrin (U-CON) Predetermined amount of the above acylated β- cyclodextrin (ACD) was dissolved in a minimum volume of acetone (from 5-15 weight/volume percent) and filtered through a micro-syringe with 0.45 μm porous filter. The filtrate was cooled and a IN sodium hydroxide aqueous solution was added to neutralize carboxylic groups in the ACD. A concentrated, cold solution (3-15 weight/volume percent) of the acetate salts of the polypeptides Lanreotide™ (D-Nal-c [Cys-Tyr-D-Trp-Lys-Val-Cys] -Thr-NH 2 ; Kinerton Ltd. , Dublin, Ireland) or Decapeptyl™ (pGlu-His- Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 ; Kinerton Ltd.) was added to acetone solution of the neutralized ACD dropwise with stirring. The product was left at 25°C for 0.5-1 hr. and then precipitated in a stirring ice-water bath. The resulting precipitate was filtered, rinsed thoroughly with water, and air dried. The product was then isolated and dried under vacuum to constant weight at room temperature. The weight of the dried composition was determined, and the composition was characterized for percent content of peptide, as measured by elemental analysis of the percent of nitrogen present in the composition (Quantitative Technologies, Inc., Whitehouse, NJ) , as reported in Table III. The particulate product was reduced in size by grinding to achieve an average particle size of about 100 μ before storage under reduced pressure. TABLE III. Preparation and Properties of Polypeptide/ Acylated / S-Cyclodextrin Conjugates (U-CON) 1 L is Lanreotide™ and D is Decapeptyl 1 Example 4: Preparation of Polypeptide Conjugates of Lactone-Grafted Acylated -Cyclodextrin (G- CON) Predetermined amount of the grafted ACD (G-ACD) was converted to a peptide composition following the same procedure used in preparing the U-CON' s in Example 3. Reaction composition and characterization data of the different G-CON's are reported in Table IV. TABLE IV. Preparation and Properties of Polypeptide/ Lactone-Grafted ACD Conjugates (G-CON) 1 L is Lanreotide™ and D is Decapeptyl™ Example 5: In Vivo Release Assay Male Sprague-Dawley rats (200-225 g; Taconic Farms) were injected intermuscularly with approximately 3 ml of either 767 mg of G-CON-19 or 922 mg of U-CON-16 or 966 mg of U-CON-16 administered in a vehicle of 2% carboxymethyl cellulose/1% Tween 20/saline. Blood samples were taken by 6 hours, 2 days, 7 days, 15 days and 22 days following administration. The concentration of Lanreotide™ in the blood was measured by standard radioimmunoassay and is reported in the following Table V. TABLE V. Lanreotide™ Release in Rat Plasma Thus, both the ungrafted composition U-CON- 19 and the grafted composition U-CON- 16 released the drug Lanreotide™ over a period of at least 22 days. Other Embodiments It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims. What is claimed is :

Claims: Claims 1. A cyclodextrin derivative, wherein at least 60 percent of the free hydroxy groups of said cyclodextrin are acylated with acyl groups where at least one of said acyl groups comprises a free carboxylic group . 2. A cyclodextrin derivative of claim 1, wherein said cyclodextrin is α-cyclodextrin, /3-cyclodextrin, or γ-cyclodextrin. 3. A cyclodextrin derivative of claim 2, wherein said acyl groups are selected from C0E 1 , where E 1 is selected from the group consisting of C 2 _ 32 carboxy alkyl, C 3 _ 32 carboxy alkenyl, C 7 _ 37 carboxyaryl, C 8 _ 38 carboxyaryl alkyl, and C 9 _ 39 carboxyaryl alkenyl and C0E 2 , where E 2 is selected from the group consisting of C^,, alkyl, C 2 . 30 alkenyl, C s _ 36 aryl, C 7 _ 37 arylalkenyl, and C 8 _ 38 aryl alkenyl, wherein at least one of said acyl group is COE j^ . 4. A cyclodextrin derivative of claim 3, wherein between 10 and 80 percent of said free hydroxy groups of said cyclodextrin are acylated with C0E 1 and between 10 and 80 percent of said cyclodextrin are acylated with C0E 2 . 5. A cyclodextrin derivative of claim 4, wherein COE ! is CO(CH 2 ) n COOH (where n = 2-3) and COE 2 is C0(CH 2 ) n CH 3 (where n = 0-5) and said cyclodextrin is -cyclodextrin. 6. A copolymer comprising said cyclodextrin derivative of claim 1, wherein said cyclodextrin derivative comprises at least one free hydroxy group which is acylated with a polyester comprising hydroxy acid monomers. 7. A copolymer of claim 6, wherein said copolymer has an average molecular weight of between 500 - 40,000 daltons. 8. A copolymer of claim 7, wherein said polyester comprises hydroxy acid monomers selected from the group consisting of lactic acid, glycolic acid, hydroxy caprolic acid, or any optically active isomer thereof . 9. A copolymer comprising said cyclodextrin derivative of claim 5, wherein said cyclodextrin derivative comprises at least one free hydroxy group which is acylated with a polyester comprising hydroxy acids . 10. A copolymer of claim 9, wherein said polyester comprises hydroxy acid monomers selected from the group consisting of lactic acid, glycolic acid, hydroxy caprolic acid, or any optically active isomer thereof and said copolymer has an average molecular weight of between 500 - 40,000 daltons. 11. A composition comprising said cyclodextrin derivative of claim 1 and a drug, said drug comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of said polypeptide present in said composition is ionically bonded to said cyclodextrin derivative. 12. A composition of claim 11, wherein said composition comprises between 1 and 30 percent, by weight, of said drug. 13. A composition of claim 12, wherein said drug is a polypeptide. 14. A composition of claim 13, wherein said polypeptide comprises between 4 and 50 amino acids. 15. A composition of claim 14, wherein said polypeptide is somatostatin, LHRH, calcitonin, or an analog thereof. 16. A composition comprising said copolymer of claim 6 and a drug, said drug comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of said polypeptide present in said composition is ionically bonded to said cyclodextrin derivative . 17. A composition of claim 16, wherein said composition comprises between 1 and 30 percent, by weight, of said drug. 18. A composition of claim 17, wherein said drug is a polypeptide. 19. A composition of claim 18, wherein said polypeptide comprises between 4 and 50 amino acids. 20. A composition of claim 19, wherein said polypeptide is somatostatin, LHRH, calcitonin, or an analog thereof.

Inventors: CORBETT JOEL THOMAS, SHALABY SHALABY W, CORBETT, JOEL, THOMAS, SHALABY, SHALABY, W.
Applicants: CORBETT JOEL THOMAS, POLY MED, SHALABY SHALABY W, CORBETT, JOEL, THOMAS, POLY-MED, SHALABY, SHALABY, W.
Application year: 1997
Main classification: C08B37
IPC codes: A61K47, C08B37